文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

去甲肾上腺素剂量报告异质性对脓毒性休克患者死亡率预测的影响

The impact of norepinephrine dose reporting heterogeneity on mortality prediction in septic shock patients.
PubMed 文献 · Crit Care · 2024-07-03
一句话结论脓毒性休克患者中去甲肾上腺素以盐制剂或基础分子报告剂量会显著改变死亡率预测,标准化为基础分子报告可能改善风险分层(作者结论)。

该研究基于MIMIC-IV数据库回顾性分析4086例脓毒性休克患者,将去甲肾上腺素剂量从基础分子转换为等效盐剂量,比较不同剂量报告方式在常用严重度剂量切点下对28天死亡率的预测能力。患者中位年龄68[57-78]岁,入院SOFA评分7[6-10],诊断时乳酸3.2[2.4-5.1] mmol/L,第1天中位峰值去甲肾上腺素剂量0.24[0.12-0.42] μg/kg/min,28天死亡率39.3%。以酒石酸氢盐和酒石酸盐报告剂量时,OR分别比基础分子报告低65(95%CI 79-43)%和67(95%CI 80-47)%,且随剂量升高差异扩大;在1 μg/kg/min阈值下,酒石酸盐报告预测死亡率为54(95%CI 52-56)%,基础分子报告为83(95%CI 80-87)%。作者认为标准化为基础分子报告可增强风险分层并改善诊疗流程。

要点

  • 在4086例脓毒性休克患者中,去甲肾上腺素以酒石酸氢盐报告时OR比基础分子报告低65(95%CI 79-43)%,以酒石酸盐报告时低67(95%CI 80-47)%。
  • 剂量报告方式导致的预测差异随去甲肾上腺素剂量升高而扩大。
  • 在1 μg/kg/min阈值下,酒石酸盐报告预测28天死亡率为54(95%CI 52-56)%,基础分子报告为83(95%CI 80-87)%。
  • 队列第1天中位峰值去甲肾上腺素剂量为0.24[0.12-0.42] μg/kg/min,28天死亡率为39.3%。
  • 作者认为标准化去甲肾上腺素剂量为基础分子报告可能增强风险分层并改善诊疗流程。

适用人群与场景

  • MIMIC-IV数据库中符合脓毒性休克诊断的4086例患者;中位年龄68[57-78]岁,入院SOFA评分7[6-10],诊断时乳酸3.2[2.4-5.1] mmol/L。

研究设计与关键结果

  • 回顾性分析MIMIC-IV数据库,纳入4086例脓毒性休克患者,比较去甲肾上腺素剂量以基础分子或等效盐剂量报告时对28天死亡率的预测能力。
  • 第1天中位峰值去甲肾上腺素剂量为0.24[0.12-0.42] μg/kg/min,28天死亡率为39.3%。
  • 以酒石酸氢盐报告的去甲肾上腺素剂量预测28天死亡率的OR比基础分子报告低65(95%CI 79-43)%。
  • 以酒石酸盐报告的去甲肾上腺素剂量预测28天死亡率的OR比基础分子报告低67(95%CI 80-47)%。
  • 剂量报告方式导致的死亡率预测差异随去甲肾上腺素剂量升高而扩大。
  • 在1 μg/kg/min阈值下,酒石酸盐报告预测28天死亡率为54(95%CI 52-56)%,基础分子报告为83(95%CI 80-87)%。

证据类型、等级与局限

  • 证据类型:基于MIMIC-IV数据库的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,将去甲肾上腺素剂量标准化为基础分子报告可能增强风险分层并改善诊疗流程;原文未据此给出具体推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Norepinephrine (NE) is a cornerstone drug in the management of septic shock, with its dose being used clinically as a marker of disease severity and as mortality predictor. However, variations in NE dose reporting either as salt formulations or base molecule may lead to misinterpretation of mortality risks and hinder the process of care.

METHODS: We conducted a retrospective analysis of the MIMIC-IV database to assess the impact of NE dose reporting heterogeneity on mortality prediction in a cohort of septic shock patients. NE doses were converted from the base molecule to equivalent salt doses, and their ability to predict 28-day mortality at common severity dose cut-offs was compared.

RESULTS: 4086 eligible patients with septic shock were identified, with a median age of 68 [57-78] years, an admission SOFA score of 7 [6-10], and lactate at diagnosis of 3.2 [2.4-5.1] mmol/L. Median peak NE dose at day 1 was 0.24 [0.12-0.42] μg/kg/min, with a 28-day mortality of 39.3%. The NE dose showed significant heterogeneity in mortality prediction depending on which formulation was reported, with doses reported as bitartrate and tartrate presenting 65 (95% CI 79-43)% and 67 (95% CI 80-47)% lower ORs than base molecule, respectively. This divergence in prediction widened at increasing NE doses. When using a 1 μg/kg/min threshold, predicted mortality was 54 (95% CI 52-56)% and 83 (95% CI 80-87)% for tartrate formulation and base molecule, respectively.

CONCLUSIONS: Heterogeneous reporting of NE doses significantly affects mortality prediction in septic shock. Standardizing NE dose reporting as base molecule could enhance risk stratification and improve processes of care. These findings underscore the importance of consistent NE dose reporting practices in critical care settings.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Morales S, Wendel-Garcia PD, Ibarra-Estrada M, et al. The impact of norepinephrine dose reporting heterogeneity on mortality prediction in septic shock patients. Crit Care. 2024. PMID: 38961499. doi:10.1186/s13054-024-05011-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。